Cargando…
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%–20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of tr...
Autores principales: | Advani, Pooja, Cornell, Lauren, Chumsri, Saranya, Moreno-Aspitia, Alvaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590321/ https://www.ncbi.nlm.nih.gov/pubmed/26451122 http://dx.doi.org/10.2147/BCTT.S90627 |
Ejemplares similares
-
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
por: Pop, Lucian, et al.
Publicado: (2019) -
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
por: Eiger, Daniel, et al.
Publicado: (2020) -
Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020) -
Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
por: Lin, Binwei, et al.
Publicado: (2023) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)